<div id="readability-page-1"><p>Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of &#34;Hold&#34; from the fifteen analysts that are  covering the firm, MarketBeat.com reports. One equities research analyst  has rated the stock with a sell recommendation, ten have assigned  a hold recommendation, three have given a buy recommendation and one  has issued  a strong buy recommendation on  the company. The average 1-year price objective among brokers that have covered the stock in the last year is $55.1364.</p><div><p><span></span><span>Get <strong>Terns Pharmaceuticals</strong> alerts:</span></p></div><p>TERN has been the topic of a number of research reports. William Blair lowered shares of Terns Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, April 7th. Citizens Jmp lowered shares of Terns Pharmaceuticals from a &#34;market outperform&#34; rating to a &#34;hold&#34; rating in a report on Thursday, March 26th. BMO Capital Markets lowered shares of Terns Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, March 26th. TD Cowen lowered shares of Terns Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $53.00 target price on the stock. in a report on Thursday, March 26th. Finally, Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Terns Pharmaceuticals in a report on Friday, March 27th.</p><p><b>View Our Latest Stock Report on Terns Pharmaceuticals</b></p><h2>Insiders Place Their Bets</h2><p>In other news, CEO Amy L. Burroughs sold 14,583 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer directly owned 288,976 shares of the company's stock, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Emil Kuriakose sold 942 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the sale, the insider directly owned 105,673 shares in the company, valued at approximately $5,574,250.75. This represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 30,108 shares of company stock worth $1,302,370. Insiders own  1.50% of the company's stock. </p><h2>Institutional Investors Weigh In On Terns Pharmaceuticals</h2><p>A number of institutional investors have recently modified their holdings of the company. Morgan Stanley boosted its stake in shares of  Terns Pharmaceuticals by 4.7% in the 4th quarter. Morgan Stanley now owns 7,945,608 shares of the company's stock valued at $321,003,000 after purchasing an additional 356,513 shares during the last quarter.  Commodore Capital LP bought a new stake in shares of  Terns Pharmaceuticals in the 3rd quarter valued at $42,807,000.  Adage Capital Partners GP L.L.C. boosted its stake in shares of  Terns Pharmaceuticals by 40.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company's stock valued at $224,220,000 after purchasing an additional 1,611,000 shares during the last quarter.  Vanguard Group Inc. boosted its stake in shares of  Terns Pharmaceuticals by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company's stock valued at $223,167,000 after purchasing an additional 964,031 shares during the last quarter.  Finally, Vestal Point Capital LP bought a new stake in shares of  Terns Pharmaceuticals in the 4th quarter valued at $181,800,000. 98.26% of the stock is owned by institutional investors. </p><h2>Terns Pharmaceuticals Price Performance</h2><p>TERN opened at $52.97 on Tuesday. Terns Pharmaceuticals has a fifty-two week low of $2.65 and a fifty-two week high of $53.19. The firm has a market capitalization of $6.12 billion, a price-to-earnings ratio of -51.42 and a beta of -0.37. The company's 50 day moving average price is $48.93 and its two-hundred day moving average price is $36.96. </p><p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06.  As a group, equities research analysts predict that  Terns Pharmaceuticals will post -1.21 EPS for the current year. </p><h2>About Terns Pharmaceuticals</h2> (Get Free Report)<p>Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.  </p><p>The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Terns Pharmaceuticals</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Terns Pharmaceuticals Right Now?</h2><p>Before you consider Terns Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.</p><p>While Terns Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TERN

SBIO

LABU

<p>Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has received a consensus recommendation of "Hold" from fifteen analysts. The breakdown includes one sell, ten hold, three buy, and one strong buy recommendations. The average 1-year price target is $55.14. Recent insider sales include CEO Amy L. Burroughs selling 14,583 shares and Emil Kuriakose selling 942 shares. Institutional investors hold 98.26% of the stock. Terns has a market cap of $6.12 billion and reported earnings of ($0.24) per share, exceeding estimates. The stock opened at $52.97, with a 52-week range of $2.65 to $53.19.</p>

Market Beat

Terns Pharmaceuticals

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

Bank of Montreal

Toronto Dominion Bank

Morgan Stanley

The Vanguard Group, Inc.

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from Analysts